Compare VLN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | IPHA |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 169.6M |
| IPO Year | N/A | 2019 |
| Metric | VLN | IPHA |
|---|---|---|
| Price | $1.83 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 4.5M | 21.6K |
| Earning Date | 02-25-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,887,000.00 | $14,839,695.00 |
| Revenue This Year | $21.84 | $22.29 |
| Revenue Next Year | $11.96 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $1.37 | $1.63 |
| 52 Week High | $3.34 | $2.63 |
| Indicator | VLN | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 48.08 |
| Support Level | $1.84 | $1.74 |
| Resistance Level | $2.15 | $1.85 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.25 | 43.75 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.